Common use of Second Product Clause in Contracts

Second Product. The Parties shall collaborate on the Development of the Second Product. The initial R&D Plan for the Second Product is attached hereto as Exhibit 4.2, and may be amended from time to time by the JSC in accordance with this Agreement ("Second Product R&D Plan"). Subject to the terms and conditions of this Agreement and in accordance with the Second Product R&D Plan, the Parties will perform the following Development activities in respect of the Second Product: (i) the Parties will collaborate on the Antigen design and the identification of the precise target; (ii) CureVac will perform the mRNA design and formulation and will conduct the pre-clinical validation; (iii) CureVac will sponsor a first Clinical Phase I Study, unless the Parties agree on a different clinical development approach within the JSC; and (iv) unless GSK replaces the Product in accordance with Section 3.6 or the Program is terminated, GSK will conduct all subsequent Development activities, including regulatory activities to obtain Regulatory Approval for such Product, which CureVac shall support, including by the clinical supply of Products.

Second Product. The Parties shall collaborate on the Development of the Second Product. The initial R&D Plan for the Second Product is attached hereto as Exhibit 4.2, and may be amended from time to time by the JSC in accordance with this Agreement ("“Second Product R&D Plan"”). Subject to the terms and conditions of this Agreement and in accordance with the Second Product R&D Plan, the Parties will perform the following Development activities in respect of the Second Product: (i) the Parties will collaborate on the Antigen design and the identification of the precise target; (ii) CureVac will perform the mRNA design and formulation and will conduct the pre-clinical validation; (iii) CureVac will sponsor a first Clinical Phase I Study, unless the Parties agree on a different clinical development approach within the JSC; and (iv) unless GSK replaces the Product in accordance with Section 3.6 or the Program is terminated, GSK will conduct all subsequent Development activities, including regulatory activities to obtain Regulatory Approval for such Product, which CureVac shall support, including by the clinical supply of Products.

Second Product. The Parties shall collaborate on the Development of the Second Product. The initial R&D Plan for the Second Product is attached hereto as Exhibit 4.2, and may be amended from time to time by the JSC in accordance with this Agreement ("Second Product R&D Plan"). Subject to the terms and conditions of this Agreement and in accordance with the Second Product R&D Plan, the Parties will perform the following Development activities in respect of the Second Product: (i) the Parties will collaborate on the Antigen design and the identification of the precise target; (ii) CureVac will perform the mRNA design and formulation and will conduct the pre-clinical validation; (iii) CureVac will sponsor a first Clinical Phase I Study, unless the Parties agree on a different clinical development approach within the JSC; and (iv) unless GSK replaces the Product in accordance with Section 3.6 or the Program is terminated, GSK will conduct all subsequent Development activities, including regulatory ​ ​ ​ activities to obtain Regulatory Approval for such Product, which CureVac shall support, including including, and subject to Section 5.3 below, by the clinical supply of Products.